Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 2/20 | 0.50 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.44 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
| ▸ | DHODH | Q02127 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5741905 | 1.00 | STAT3 (0.50) | STAT3CTDSP1SIRT5CYP2D6TLR9 | |
| SCHEMBL10458162 | 0.84 | STAT3 (0.54) | STAT3CTDSP1SIRT5CYP2D6TLR9 | |
| SCHEMBL4727494 | 0.82 | STAT3 (0.56) | STAT3CTDSP1SIRT5GAAPKM | |
| SCHEMBL15625927 | 0.81 | PTGS2 (0.42) | ALDH1A1CA1CA2MMP1KMT2A | |
| Water SCHEMBL2978476 | 0.81 | STAT3 (0.55) | STAT3CTDSP1SIRT5GAAPKM | |
| SCHEMBL5870519 | 0.81 | STAT3 (0.51) | STAT3CTDSP1SIRT5CYP2D6DHODH | |
| SCHEMBL26713425 | 0.81 | STAT3 (0.43) | STAT3CTDSP1SIRT5CYP2D6TLR9 | |
| SCHEMBL7342597 | 0.80 | STAT3 (0.57) | STAT3CTDSP1SIRT5CYP2D6GAA | |
| SCHEMBL10176520 | 0.79 | STAT3 (0.42) | STAT3CTDSP1SIRT5CYP2D6TLR9 | |
| SCHEMBL1994912 | 0.79 | STAT3 (0.60) | STAT3CTDSP1SIRT5GAAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1358183-B1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2006-04-12 | — | — | EP | disclosed |
| US-20050070598-A1 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2005-03-31 | — | — | US | disclosed |
| US-20050020588-A1 | Cysteine protease inhibitors | PEPTIMMUNE, INC. | 2005-01-27 | — | — | US | disclosed |
| US-20040229915-A1 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2004-11-18 | — | — | US | disclosed |
| EP-1413580-A1 | Furanone derivatives as inhibitors of Cathepsin S | Medivir UK Ltd (GB) | 2004-04-28 | — | — | EP | disclosed |
| EP-1178986-B1 | FURANONE DERIVATIVES AS INHIBITORS OF CATHEPSIN S | MEDIVIR UK LTD (GB) | 2004-02-25 | — | — | EP | disclosed |
| EP-1358183-A2 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2003-11-05 | — | — | EP | disclosed |
| US-20030203900-A1 | Cysteine protease inhibitors | MEDIVIR UK LTD (GB) | 2003-10-30 | — | — | US | disclosed |
| US-20030186962-A1 | Cysteine protease inhibitors | MEDIVIR AB (SE) | 2003-10-02 | — | — | US | disclosed |
| EP-1345931-A2 | CYSTEINE PROTEASE INHIBITORS | Medivir UK Ltd (GB) | 2003-09-24 | — | — | EP | disclosed |
| US-20030171434-A1 | Branched amino acids | MEDIVIR UK LIMITED (GB) | 2003-09-11 | — | — | US | disclosed |
| WO-2002088106-A2 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2002-11-07 | — | — | WO | disclosed |
| WO-2002040462-A2 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR UK LIMITED (GB) | 2002-05-23 | — | — | WO | disclosed |
| EP-1178986-A2 | FURANONE DERIVATIVES AS INHIBITORS OF CATHEPSIN S | Medivir UK Ltd (GB) | 2002-02-13 | — | — | EP | disclosed |
| WO-2000069855-A2 | FURANONE DERIVATIVES AS INHIBITORS OF CATHEPSIN S | MEDIVIR UK LIMITED (GB) | 2000-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186962-A1 | Cysteine protease inhibitors | C1R, CTSS, CTSZ | STAT3 4642/4885CTDSP1 2441/4885SIRT5 2652/4885 |
| US-20050070598-A1 | Cysteine protease inhibitors | CTRL, CTSZ, CTSS | STAT3 4570/4885CTDSP1 2676/4885SIRT5 2085/4885 |
| US-20050020588-A1 | Cysteine protease inhibitors | CTSS, CTSE, CTSV | STAT3 3307/4885CTDSP1 1999/4885SIRT5 1072/4885 |
| US-20040229915-A1 | Cysteine protease inhibitors | C1R, CTRL, CTSK | STAT3 4664/4885CTDSP1 2490/4885SIRT5 3480/4885 |
| US-20030203900-A1 | Cysteine protease inhibitors | CTSS, CTSE, CTSV | STAT3 3307/4885CTDSP1 1999/4885SIRT5 1072/4885 |
| US-20030171434-A1 | Branched amino acids | BCAT1, BCAT2, ANPEP | STAT3 2243/4885CTDSP1 3080/4885SIRT5 3534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.